|
業務類別
|
Biotechnology |
|
業務概覽
|
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces. |
| 公司地址
| 822 A1A North, Suite 306, Ponte Vedra, FL, USA, 32082 |
| 電話號碼
| +1 904 300-0701 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.cadrenal.com |
| 員工數量
| 5 |
| Mr. Matthew K. Szot |
Chief Financial Officer and Principal Accounting Officer |
美元 459.72K |
31/03/2026 |
| Dr. James J. Ferguson, III,M.D. |
Chief Medical Officer |
美元 457.41K |
31/03/2026 |
| Mr. Jeffrey Cole |
Chief Operating Officer |
-- |
31/03/2026 |
| Mr. Quang X. Pham |
Chairman of the Board and Chief Executive Officer |
美元 751.28K |
31/03/2026 |
|
|
| Dr. Lee Scott Golden, M.D. |
Independent Director |
31/03/2026 |
| Dr. Glynn Wilson,PhD |
Independent Director |
31/03/2026 |
| Mr. Steven Zelenkofske |
Independent Director |
31/03/2026 |
| Mr. John Raymond Murphy |
Independent Director |
31/03/2026 |
| Mr. Quang X. Pham |
Chairman of the Board and Chief Executive Officer |
31/03/2026 |
|
|
|
|
